NASDAQ:ELTX | Free Cash Flow | Elicio Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$11.65M
2025-12-31-$6.8M$16,000.00-$6.81M
2025-03-31-$10.12M
2024-12-31-$8.74M$45,000.00-$8.79M
2024-03-31-$12.12M$0.00-$12.12M
2023-12-31-$9.9M$0.00-$9.9M
2023-03-31-$8.14M$17,000.00-$8.16M
2022-12-31-$7.28M$95,000.00-$7.37M
2022-03-31-$15.65M$0.00-$15.65M
2021-12-31-$14.36M$36,000.00-$14.4M-96.70%
2021-03-31-$12.55M$41,000.00-$12.59M
2020-12-31$20.59M$10,000.00$20.58M
2020-03-31-$8.73M$20,000.00-$8.75M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$36.95M$16,000.00-$36.97M
2024-12-31-$37.07M$87,000.00-$37.16M
2023-12-31-$32.69M$66,000.00-$32.76M
2022-12-31-$22.18M$654,000.00-$22.83M
2021-12-31-$52.64M$382,000.00-$53.03M
2020-12-31-$22.89M$41,000.00-$22.93M